Quick Answer
Opus Genetics, Inc. reported Cash And Cash Equivalents At Carrying Value of $45.09 million for the year ending 2025.
- Opus Genetics, Inc. showed an increase of +48.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Opus Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2008 to 2025), Opus Genetics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 12,115.5%.
- Historical annual values: Fiscal year 2025: $45.09 million | Fiscal year 2024: $30.32 million | Fiscal year 2023: $50.50 million | Fiscal year 2022: $42.63 million | Fiscal year 2021: $24.53 million | Fiscal year 2018: $8.74 million | Fiscal year 2017: $8.90 million | Fiscal year 2016: $11.58 million | Fiscal year 2015: $10.20 million | Fiscal year 2014: $9.83 million | Fiscal year 2013: $18.69 million | Fiscal year 2012: $13.49 million | Fiscal year 2011: $9.86 million | Fiscal year 2010: $12.34 million | Fiscal year 2009: $7.30 million | Fiscal year 2008: $369.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: